Frontline treatment of elderly non transplant‐eligible multiple myeloma patients using CyBorD with or without thalidomide‐based consolidation: a retrospective multi‐centre analysis of real‐world data-Reference-Cited by-同舟云学术

Frontline treatment of elderly non transplant‐eligible multiple myeloma patients using CyBorD with or without thalidomide‐based consolidation: a retrospective multi‐centre analysis of real‐world data

Published:2019-07-12 Issue:4 Volume:187 Page:470-477
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Chan Henry¹^ORCID,Chai Kern²,Shih Steven³,Lewsey Rebecca¹,Chen Kevin¹,McDiarmid Bridgett²,Jackson Sharon³,Simpson David¹

Affiliation:

1. Department of Haematology Waitemata District Health Board Auckland

2. Department of Haematology Southern District Health Board Dunedin New Zealand

3. Department of Haematology Counties Manukau District Health Board Auckland New Zealand

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16095

Reference26 articles.

1. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

2. Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial

3. Treatment patterns and outcomes in elderly patients with multiple myeloma

4. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

5. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China;Frontiers in Pharmacology;2023-01-12

2. Multiple Myeloma in Patients over 80: A Real World Retrospective Study of First Line Conservative Approach with Bortezomib Dexamethasone Doublet Therapy and Mini-Review of Literature;Cancers;2022-09-28

3. Machine Learning–Based Overall Survival Prediction of Elderly Patients With Multiple Myeloma From Multicentre Real-Life Data;Frontiers in Oncology;2022-06-30

4. The Nitrogen Mustards;Pharmacological Reviews;2022-06-16

5. Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma;Annals of Hematology;2021-07-31